Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi: 10.1007/s10637-025-01551-6 68 DAnnaGHanurryEPipernoAScalaA
placed on Category 2 (under evaluation) Virginia pharmacy board / Defers to federal USP and FDA compounding standards Legal access path / Physician prescription plus 503A state-licensed compounding pharmacy Scheduled drug status / Not a DEA-scheduled controlled substance as of 2025 Clinical evidence / No Phase III RCTs completed
Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial
Yes, when given by a trained provider
US$ 27.76
US$ 20.24
US$ 28.81
US$ 21.73
US$ 29.71
US$ 29.79
